FDA warns Stryker on quality issues, marketing practices

(Reuters) – Orthopedic implant maker Stryker Corp said it received a warning letter from the U.S. Food and Drug Administration related to quality concerns at its Portage, Michigan facility. The letter, which followed an inspection of the facility in November, also noted that Stryker failed to notify the regulator of a product recall and had been marketing devices without required approvals. The FDA acknowledged that Stryker has submitted corrective action plans for the quality and recall issues, Stryker said. …